The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Abstract
The epidemic of type 2 diabetes in the latter part of the 20th and in the early 21st century, and the recognition that achieving specific glycemic goals can substantially reduce morbidity, have made the effective treatment of hyperglycemia a top priority (1–3). While the management of hyperglycemia, the hallmark metabolic abnormality associated with type 2 diabetes, has historically had center stage in the treatment of diabetes, therapies directed at other coincident features, such as dyslipidemia, hypertension, hypercoagulability, obesity, and insulin resistance, have also been a major focus of research and therapy. Maintaining glycemic levels as close to the nondiabetic range as possible has been demonstrated to have a powerful beneficial impact on diabetes-specific complications, including retinopathy, nephropathy, and neuropathy in the setting of type 1 diabetes (4,5); in type 2 diabetes, more intensive treatment strategies have likewise been demonstrated to reduce complications (6–8). Intensive glycemic management resulting in lower HbA1c (A1C) levels has also been shown to have a beneficial effect on cardiovascular disease (CVD) complications in type 1 diabetes (9,10); however, the role of intensive diabetes therapy on CVD in type 2 diabetes remains under active investigation (11,12). Some therapies directed at lowering glucose levels have additional benefits with regard to CVD risk factors, while others lower glucose without additional benefits. The development of new classes of blood glucose–lowering medications to supplement the older therapies, such as lifestyle-directed interventions, insulin, sulfonylureas, and metformin, has increased the treatment options for type 2 diabetes. Whether used alone or in combination with other blood glucose–lowering interventions, the availability of the newer agents has provided an increased number of choices for practitioners and patients and heightened uncertainty regarding the most appropriate means of treating this widespread disease. Although numerous reviews on the …
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Self-citationOhkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Self-citationCardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J.-P., & Colette, C. (2006) · JAMA · doi:10.1001/jama.295.14.1681 · Cited by 2,444
Pories, W. J., Swanson, M. S., MacDonald, K. G., Long, S. B., Morris, P. G., Brown, B. M., Barakat, H. A., deRamon, R. A., Israel, G., Dolezal, J. M., et al. (1995) · Annals of Surgery · doi:10.1097/00000658-199509000-00011 · Cited by 2,293
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Standards of Medical Care in Diabetes–2006
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s4 · Cited by 1,885
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Self-citationThe Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
Borch‐Johnsen, K., Neil, A., Balkau, B., Larsen, S. H., Nissinen, A. E. T., Pekkanen, J., Keinanen-Kiukaanniemi, S. M., Hiltunen, L. A., Kivelä, S., Tuomilehto, J. O., et al. (1999) · The Lancet · Cited by 1,272
Self-citationReichard, P., Nilsson, B.-Y., & Rosenqvist, U. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307293290502 · Cited by 1,202
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Khaw, K.-T. (2001) · BMJ · doi:10.1136/bmj.322.7277.15 · Cited by 1,017
Khaw, K.-T., Wareham, N., Bingham, S., Luben, R., Welch, A., & Day, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00006 · Cited by 974
Intensive Diabetes Therapy and Carotid Intima–Media Thickness in Type 1 Diabetes Mellitus
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa022314 · Cited by 815
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Self-citationGoldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 795
Self-citationThe Look AHEAD Research Group (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00064-3 · Cited by 767
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Standards of Medical Care in Diabetes
American Diabetes Association (2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s15 · Cited by 683
A desktop guide to Type 2 diabetes mellitus
European Diabetes Policy Group, 1. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00166.x · Cited by 670
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
Yki-Järvinen, H., Dressler, A., Ziemen, M., & HOE 901/300s Study Group (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1130 · Cited by 579
The Diabetes Prevention Program Research Group (2005) · Diabetes Care · doi:10.2337/diacare.28.4.888 · Cited by 572
Initiating Insulin Therapy in Type 2 Diabetes
Raskin, P., Allen, E., Hollander, P., Lewin, A., Gabbay, R. A., Hu, P., Bode, B., Garber, A., & for the INITIATE Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.2.260 · Cited by 560
Fonseca, V., Rosenstock, J., Patwardhan, R., & Salzman, A. (2000) · JAMA · doi:10.1001/jama.283.13.1695 · Cited by 540
Glycosylated Hemoglobin Predicts the Incidence and Progression of Diabetic Retinopathy
Klein, R. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410190112033 · Cited by 529
Glycosylated Hemoglobin Predicts the Incidence and Progression of Diabetic Retinopathy
Klein, R. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.260.19.2864 · Cited by 528
Thiazolidinedione Use and Bone Loss in Older Diabetic Adults
Schwartz, A. V., Sellmeyer, D. E., Vittinghoff, E., Palermo, L., Lecka-Czernik, B., Feingold, K. R., Strotmeyer, E. S., Resnick, H. E., Carbone, L., Beamer, B. A., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2226 · Cited by 500
Basal Insulin Therapy in Type 2 Diabetes
Rosenstock, J., Schwartz, S. L., Clark, C. M., Park, G. D., Donley, D. W., & Edwards, M. B. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.631 · Cited by 478
Krolewski, A. S., Laffel, L. M. B., Krolewski, M., Quinn, M., & Warram, J. H. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505113321902 · Cited by 452
Esposito, K., Giugliano, D., Nappo, F., & Marfella, R. (2004) · Circulation · doi:10.1161/01.cir.0000134501.57864.66 · Cited by 440
Hypoglycemia in Type 2 Diabetes
Zammitt, N. N., & Frier, B. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2948 · Cited by 435
Yki-Järvinen, H., Ryysy, L., Nikkilä, K., Tulokas, T., Vanamo, R., & Heikkilä, M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-5-199903020-00002 · Cited by 433
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetologia · doi:10.1007/s00125-006-0316-2 · Cited by 420
Self-citationBonora, E., & Muggeo, M. (2001) · Diabetologia · doi:10.1007/s001250100020 · Cited by 420
Janka, H. U., Plewe, G., Riddle, M. C., Kliebe-Frisch, C., Schweitzer, M. A., & Yki-Järvinen, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.254 · Cited by 414
Groop, L. C. (1992) · Diabetes Care · doi:10.2337/diacare.15.6.737 · Cited by 408
Should minimal blood glucose variability become the gold standard of glycemic control?
Hirsch, I. B., & Brownlee, M. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2004.10.001 · Cited by 405
The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2006) · Diabetes Care · doi:10.2337/dc06-0293 · Cited by 377
Self-Monitoring of Blood Glucose in Patients With Type 2 Diabetes Who Are Not Using Insulin
Welschen, L. M. C., Bloemendal, E., Nijpels, G., Dekker, J. M., Heine, R. J., Stalman, W. A. B., & Bouter, L. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1510 · Cited by 374
Self-citationInitial management of glycemia in type 2 diabetes mellitus
Nathan, D. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp021106 · Cited by 359
Abraira, C., Colwell, J. A., Nuttall, F. Q., Sawin, C. T., Nagel, N. J., Comstock, J. P., Emanuele, N. V., Levin, S. R., Henderson, W., Lee, H. S., et al. (1995) · Diabetes Care · doi:10.2337/diacare.18.8.1113 · Cited by 355
(2001) · PubMed · Cited by 344
Hypoglycemia in patients with type 2 diabetes mellitus
Miller, C. D., Phillips, L. S., Ziemer, D. C., Gallina, D. L., Cook, C. B., & El-Kebbi, I. M. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.13.1653 · Cited by 341
Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Van de Laar, F. A., Lucassen, P. L., Akkermans, R. P., Van de Lisdonk, E. H., Rutten, G. E., & Van Weel, C. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003639.pub2 · Cited by 335
Hollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307
Selvin, E., Coresh, J., Golden, S. H., Brancati, F. L., Folsom, A. R., & Steffes, M. W. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.16.1910 · Cited by 289
Holstein, A., Plaschke, A., & Egberts, E. (2001) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.235 · Cited by 264
Hollander, P. A., Blonde, L., Rowe, R., Mehta, A. E., Milburn, J. L., Hershon, K. S., Chiasson, J.-L., Levin, S. R., & for the Exubera Phase III Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2356 · Cited by 264
Glucose Control and the Renal and Retinal Complications of Insulin-dependent Diabetes
Chase, H. P. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03420080075034 · Cited by 256
Glucose Control and the Renal and Retinal Complications of Insulin-dependent Diabetes
Chase, H. P. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.261.8.1155 · Cited by 254
Khan, M. A., St. Peter, J. V., & Xue, J. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.708 · Cited by 250
Amylin Agonists: A Novel Approach in the Treatment of Diabetes
Schmitz, O., Brock, B., & Rungby, J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s233 · Cited by 239
Biologic actions and therapeutic potential of the proglucagon-derived peptides
Drucker, D. J. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0017 · Cited by 230
Trento, M., Passera, P., Bajardi, M., Tomalino, M., Grassi, G., Borgo, E., Donnola, C., Cavallo, F., Bondonio, P., & Porta, M. (2002) · Diabetologia · doi:10.1007/s00125-002-0904-8 · Cited by 209
Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus
Cefalu, W. T., Skyler, J. S., Kourides, I. A., Landschulz, W. H., Balagtas, C. C., Cheng, S.-L., Gelfand, R. A., & for the Inhaled Insulin Study Group* (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-3-200102060-00011 · Cited by 199
Insulin-sensitive and insulin-insensitive types of diabetes mellitus.
Himsworth, H. P., & Kerr, R. B. (1939) · Cited by 193
Colagiuri, S., Cull, C. A., Holman, R. R., & For the UKPDS Group (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1410 · Cited by 183
Self-citationRepaglinide Versus Nateglinide Monotherapy
Rosenstock, J., Hassman, D. R., Madder, R. D., Brazinsky, S. A., Farrell, J., Khutoryansky, N., Hale, P. M., & for the Repaglinide Versus Nateglinide Comparison Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1265 · Cited by 180
Rosiglitazone and Cardiovascular Risk
Psaty, B. M., & Furberg, C. D. (2007) · New England Journal of Medicine · doi:10.1056/nejme078099 · Cited by 178
A Real-World Approach to Insulin Therapy in Primary Care Practice
Hirsch, I. B., Bergenstal, R. M., Parkin, C. G., Wright, E., & Buse, J. B. (2005) · Clinical Diabetes · doi:10.2337/diaclin.23.2.78 · Cited by 170
Self-citationHuang, E. S., Meigs, J. B., & Singer, D. E. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00978-0 · Cited by 167
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2006) · The Cochrane Database of Systematic Reviews (Complete Reviews) · doi:10.1002/14651858.cd002967.pub2 · Cited by 163
Epidemiological Correlates of NIDDM in Hispanics, Whites, and Blacks in the u.s. Population
Harris, M. I. (1991) · Diabetes Care · doi:10.2337/diacare.14.7.639 · Cited by 160
Rosenstock, J., Zinman, B., Murphy, L. J., Clement, S. C., Moore, P., Bowering, C. K., Hendler, R., Lan, S.-P., & Cefalu, W. T. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00005 · Cited by 158
Self-citationInsulin Glulisine Provides Improved Glycemic Control in Patients With Type 2 Diabetes
Dailey, G., Rosenstock, J., Moses, R. G., & Ways, K. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2363 · Cited by 153
Is HbA1c Affected by Glycemic Instability?
Derr, R. L., Garrett, E., Stacy, G. A., & Saudek, C. D. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2728 · Cited by 152
Pontiroli, A. E., Folli, F., Paganelli, M., Micheletto, G., Pizzocri, P., Vedani, P., Luisi, F., Perego, L., Morabito, A., & Bressani Doldi, S. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2703 · Cited by 129
Rosiglitazone and cardiotoxicity –weighing the evidence
Nathan, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejme078117 · Cited by 126
The Record on Rosiglitazone and the Risk of Myocardial Infarction
Psaty, B. M., & Furberg, C. D. (2007) · New England Journal of Medicine · doi:10.1056/nejme078116 · Cited by 120
Schwartz, S., Sievers, R., Strange, P., Lyness, W. H., Hollander, P., & For The INS-2061 Study Team (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2238 · Cited by 117
Glibenclamide vs Gliclazide in Type 2 Diabetes of the Elderly
Tessier, D., Dawson, K., Tétrault, J. P., Bravo, G., & Meneilly, G. S. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00256.x · Cited by 116
Gerich, J., Raskin, P., Jean-Louis, L., Purkayastha, D., & Baron, M. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2093 · Cited by 116
GENUTH, S. M. (1990) · Diabetes Care · doi:10.2337/diacare.13.12.1240 · Cited by 115
Maturity onset diabetes mellitus: response to intensive dietary management.
Hadden, D. R., Montgomery, D. A., Skelly, R. J., Trimble, E. R., Weaver, J. A., Wilson, E. A., & Buchanan, K. D. (1975) · BMJ · doi:10.1136/bmj.3.5978.276 · Cited by 102
Warram, J. H., Scott, L. J., Ficociello, L., Wantman, M., Cohen, S., Laffel, L. M., RYAN, L. M., & Krolewski, A. S. (2000) · Diabetes · doi:10.2337/diabetes.49.1.94 · Cited by 97
Current Therapeutic Options in Type 2 Diabetes Mellitus: A Practical Approach
Sheehan, M. T. (2003) · Clinical Medicine & Research · doi:10.3121/cmr.1.3.189 · Cited by 96
Tanaka, Y., Atsumi, Y., Matsuoka, K., Onuma, T., Tohjima, T., & Kawamori, R. (1998) · Diabetes Care · doi:10.2337/diacare.21.1.116 · Cited by 93
Alcohol and the risk of myocardial infarction
Flesch, M., Rosenkranz, S., Erdmann, E., & Böhm, M. (2001) · Basic Research in Cardiology · doi:10.1007/s003950170062 · Cited by 87
Pharmacology of the Meglitinide Analogs
Malaisse, W. J. (2003) · Treatments in Endocrinology · doi:10.2165/00024677-200302060-00004 · Cited by 78
Bailey, C. J., Bagdonas, A., Rubes, J., McMorn, S. O., Donaldson, J., Biswas, N., & Stewart, M. W. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.10.012 · Cited by 73
Improved Glycemic Control Without Weight Gain Using Triple Therapy in Type 2 Diabetes
Strowig, S. M., Avilés-Santa, L. M., & Raskin, P. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1577 · Cited by 69
NATHAN, D. M., ROUSSELL, A., & GODINE, J. E. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-334 · Cited by 67
Self-citationADVANCE Collaborative Group (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01596.x · Cited by 62
Kaiser, T., & Sawicki, P. T. (2004) · Diabetologia · doi:10.1007/s00125-003-1318-y · Cited by 62
Rosiglitazone — Continued Uncertainty about Safety
Drazen, J. M., Morrissey, S., & Curfman, G. (2007) · New England Journal of Medicine · doi:10.1056/nejme078118 · Cited by 56
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
The Burden of Treatment Failure in Type 2 Diabetes
Simons‐Morton, D. G., GENUTH, S. M., Byington, R. P., Gerstein, H. C., & Friedewald, W. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.761 · Cited by 24
Cryer, P. E. (2006) · Diabetes Care · doi:10.2337/dc-06-1670 · Cited by 15
Jellinger, P. S., Lebovitz, H. E., Davidson, J. A., & on behalf of the ACE/AACE Outpatient Glycemic Control Implementation Task Force (2007) · Diabetes Care · doi:10.2337/dc06-2373 · Cited by 11
Basic Approach to Managing Hyperglycemia for the Nonendocrinologist
Deeg, M. A. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.003 · Cited by 10
Parkin, C. G., & Davidson, J. A. (2006) · Diabetes Care · doi:10.2337/dc06-1858 · Cited by 6
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5
Kristensen, J., Frandsen, K. B., Bayer, T. A., et al. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(00)81703-9 · Cited by 5
Porta, M., & Trento, M. (2006) · Diabetes Care · doi:10.2337/dc06-1828 · Cited by 4
Cited by
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Self-citationStandards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Translating the A1C assay into estimated average glucose values
Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., Heine, R. J., & for the A1c-Derived Average Glucose (ADAG) Study Group (2008) · Diabetes Care · doi:10.2337/dc08-0545 · Cited by 1,812
Self-citation
Metadata
- Authors
- Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-08-01
- Volume
- 29
- Issue
- 8
- Pages
- 1963-1972
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2153449155
- Cited by
- 1,203
- References
- 116
- FWCI
- 108.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.